7.1 Treatments Administered .................................................................................. 7.1.1 Method of Treatment Assignment ............................................................ 7.2 Blinding............................................................................................................. 7.3 Dosage Modification ......................................................................................... 7.3.1 Treatment Delay ....................................................................................... 7.3.2 BMS-986226 Dose-limiting Toxicities ..................................................... 7.3.3 Management Algorithms for Immuno-oncology Agents .......................... 7.3.4 Dose Delays Due To Toxicity .................................................................. 7.3.5 Exceptions to Permanent Discontinuation Criteria ................................. 7.3.6 Management of Drug-related Infusion Reactions.................................... 7.4 Preparation/Handling/Storage/Accountability .................................................. 7.4.1 Retained Samples for Bioavailability / Bioequivalence ........................... 7.5 Treatment Compliance ...................................................................................... 7.6 Concomitant Therapy........................................................................................ 7.6.1 Prohibited and/or Restricted Treatments................................................. 7.6.1.1 Imaging Restriction and Precautions ............................................. 7.6.2 Permitted Therapy ................................................................................... 7.6.3 Palliative Local Therapy .......................................................................... 7.7 Treatment After the End of the Study ............................................................... 8 DISCONTINUATION CRITERIA ...........................................................................